At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease.

Blockbuster GLP-1 medications are changing patient care, impacting surgery volumes and reshaping the financial landscape of the healthcare industry.

Last year, Wegovy won a new Food and Drug Administration approval to reduce the risk of heart attacks and other ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Singer Michael Trotter Jr of The War and Treaty, chef Franklin Becker of “Top Chef Masters,” and a beauty salon owner ...

Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the science behind weight management, and the role of medications like Ozempic in ...

The CEO of <strong>Novo Nordisk</strong> warned of the impact of tariffs on the pharmaceutical industry. Weight-loss drugs, including Ozempic and Wegovy, could cost ...